<DOC>
	<DOCNO>NCT01272817</DOCNO>
	<brief_summary>Allogeneic transplant match sibling treatment variety illnesses include bone marrow failure state , leukemia , myelodysplastic myeloproliferative syndrome , lymphoma , myeloma use nonmyeloablative preparative regimen .</brief_summary>
	<brief_title>Nonmyeloablative Allogeneic Transplant</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Age &gt; 55 year 2 . Age &lt; 55 LVEF &lt; 45 % creatinine clearance &lt; 60 ml/min 3 . Ability cover cost transplant , necessary medication , transportation/housing . 4 . Caregiver must available outpatient Guidelines CladribineMelphalanbased conditioning : Bone Marrow Failure States Severe Aplastic Anemia ( relapse follow immunosuppressive therapy ) Paroxysmal Nocturnal Hemoglobinuria ( poor prognostic feature hemosiderosis ) AML ( first CR except ( 15 ; 17 ) , inv16 , ( 8,21 ) ; second CR ; relapse fail second induction attempt ) ALL ( first CR least one poor prognostic feature ; second great CR ; relapse fail reinduction attempt ) MDS ( RAEB , RAEBiT , CMMoL ) CML ( chronic phase ; accelerated phase ; blast phase follow reinduction attempt ; 2nd chronic accelerate phase follow gleevec therapy Hodgkin 's lymphoma ( first great relapse ) NonHodgkin 's Lymphoma Aggressive Histology ( include T Cell NHL ) Incomplete response induction Second CR Sensitive refractory relapse Indolent Histology Second great relapse Mantle Cell Lymphoma ( Stage must receive induction chemotherapy ) Multiple Myeloma ( 10 % residual plasmacytosis follow anthracyclinebased chemotherapy residual disease follow autologous transplant ) Waldenstrom Macroglobulinemia ( must fail either purine analoguebased chemotherapy ( Fludara 2CdA ) standard CVP therapy ; hyperviscosity cytopenia ) Guidelines total lymphoid irradiationbased condition MDS ( RA , RARS ) CLL ( Rai stage III IV must receive least two different treatment regimen past ) Breast Cancer ( symptomatic metastatic disease , fail standard chemotherapy ) Renal Cell Cancer ( metastatic disease multiple site ) Malignant Melanoma ( metastatic disease multiple site ) Sarcoma ( subtypes presently , unresectable metastatic disease ) Ovarian Cancer ( stage III IV , platinum insensitive disease , i.e . progression within 6 month initial platinum chemotherapy ) Thymoma ( unresectable disease ) 1 . Prior allogeneic stem cell bone marrow transplant 2 . Current past history invasive mycotic infection 3 . Breast Feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Nonmyeloablative transplant</keyword>
	<keyword>Allogeneic transplant</keyword>
	<keyword>Transplant</keyword>
</DOC>